Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2194014

Acorda Therapeutics, Inc. - Product Pipeline Review - 2012

Description:
Acorda Therapeutics, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Acorda Therapeutics, Inc. - Product Pipeline Review - 2012” provides data on the Acorda Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Acorda Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Acorda Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Acorda Therapeutics, Inc. - Brief Acorda Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Acorda Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Acorda Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Acorda Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Acorda Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Acorda Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Acorda Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Acorda Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Acorda Therapeutics, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Acorda Therapeutics, Inc.; Acorda Therapeutics, Inc. - Key Therapeutics; Acorda Therapeutics, Inc. - Pipeline Overview and Promising Molecules; Acorda Therapeutics, Inc. - News; Acorda Therapeutics, Inc. - Latest Updates; Acorda Therapeutics, Inc. - Pipeline; Acorda Therapeutics, Inc. - Discontinued/Dormant Projects
 
Contents:
2
List of Tables 5
List of Figures 5
Acorda Therapeutics, Inc. Snapshot 6
Acorda Therapeutics, Inc. Overview 6
Key Information 6
Key Facts 6
Acorda Therapeutics, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
Acorda Therapeutics, Inc. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Acorda Therapeutics, Inc. – Pipeline Products Glance 11
Acorda Therapeutics, Inc. Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Acorda Therapeutics, Inc. – Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Acorda Therapeutics, Inc. – Drug Profiles 14
AC105 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Chondroitinase Program 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
GGF2 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
rHIgM22 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Acorda Therapeutics, Inc. – Pipeline Analysis 20
Acorda Therapeutics, Inc. – Pipeline Products by Therapeutic Class 20
Acorda Therapeutics, Inc. – Pipeline Products By Target 21
Acorda Therapeutics, Inc. – Pipeline Products by Route of Administration 22
Acorda Therapeutics, Inc. – Pipeline Products By Mechanism of Action 23
Acorda Therapeutics, Inc. – Recent Pipeline Updates 24
Acorda Therapeutics, Inc. - Dormant Projects 25
Acorda Therapeutics, Inc. – Company Statement 26
Acorda Therapeutics, Inc. – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Acorda Therapeutics, Inc., Recent Developments 31
Acorda Therapeutics, Inc.- Press Release 31
Jun 12, 2012: Acorda Therapeutics Initiates Ampyra Proof-Of-Concept Study In Patients With Post-Stroke Deficits 31
May 31, 2012: Acorda To Present New Research Data And Clinical Usage Of Ampyra At 4th Collaborative Meeting Of CMSC And ACTRIMS 31
Apr 25, 2012: Acorda Therapeutics Presents AMPYRA Long-Term Safety And Efficacy Data At 64th American Academy Of Neurology Annual Meeting 32
Oct 22, 2009: Acorda Announces Extension Of Fampridine-SR 33
Feb 02, 2009: Acorda Submits New Drug Application For Fampridine-SR 33
Oct 14, 2009: FDA committee Announces Positive Vote For Fampridine-SR 34
Oct 22, 2009: Acorda Therapeutics Announces Extension of Fampridine-SR PDUFA Goal Date to January 22, 2010 35
Oct 14, 2009: Acorda Therapeutics Announces Positive Vote by FDA Advisory Committee for Fampridine-SR 35
Oct 09, 2009: Acorda Therapeutics Announces Posting of Briefing Documents for October 14 FDA Advisory Committee Meeting on Fampridine-SR 36
Sep 15, 2009: Acorda Therapeutics Announces Data on Retention Rates and Safety from Two Phase 3 Fampridine-SR Extension Studies 36
Sep 10, 2009: Acorda Therapeutics Announces Interim Analysis of Two-Year Efficacy and Safety Data from Phase 3 Fampridine-SR Extension Study 37
Aug 25, 2009: Acorda Therapeutics Reports Date of FDA Advisory Committee Review of Fampridine-SR for Improvement of Walking Ability in People with MS 37
Jul 01, 2009: Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S. 38
Jun 08, 2009: Acorda Therapeutics Announces Eligibility of Fampridine-SR for Centralized Review in Europe 39
May 06, 2009: Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing 39
Apr 23, 2009: Acorda Therapeutics Resubmits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis 40
Mar 31, 2009: Acorda Therapeutics Receives Refuse to File Letter from FDA on Fampridine-SR NDA 40
Feb 26, 2009: Data Published in The Lancet Show Fampridine-SR Improved Walking Ability in People with Multiple Sclerosis 40
Feb 02, 2009: Acorda Therapeutics Submits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis 41
Financial Deals Landscape 43
Acorda Therapeutics, Inc., Deals Summary 43
Acorda Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details 44
Asset Transactions 44
Acorda Therapeutics Acquires Aminopyridine and Pre-Clinical Assets From Neurorecovery 44
Acorda Therapeutics Acquires US Rights Of Zanaflex From Elan 46
Private Equity 48
Acorda Therapeutics Raises $10 Million From Paul Capital 48
Partnerships 50
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 50
Licensing Agreements 51
Acorda Therapeutics Enters Into Licensing Agreement With Medtronic For AC105 51
Biogen Idec Enters Into An Agreement With Acorda Therapeutics 53
Equity Offering 55
Acorda Therapeutics Completes Public Offering Of $131 Million 55
Acorda Therapeutics Completes Public Offering Of $67 Million 57
Acorda Therapeutics Completes Public Offering Of $80 Million 59
Acorda Therapeutics Completes Private Placement Of $31.5 Million 61
Acorda Therapeutics Completes IPO Of $36.45 Million 63
Acorda Therapeutics Completes Private Placement Of $11.5 Million 65
Acquisition 66
Acorda Therapeutics To Acquire Neuronex For Up To $141 Million 66
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Tables
Acorda Therapeutics, Inc., Key Information 6
Acorda Therapeutics, Inc., Key Facts 6
Acorda Therapeutics, Inc. – Pipeline by Indication, 2012 8
Acorda Therapeutics, Inc. – Pipeline by Stage of Development, 2012 9
Acorda Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012 10
Acorda Therapeutics, Inc. – Phase II, 2012 11
Acorda Therapeutics, Inc. – Phase I, 2012 12
Acorda Therapeutics, Inc. – Pre-Clinical, 2012 13
Acorda Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012 20
Acorda Therapeutics, Inc. - Pipeline By Target, 2012 21
Acorda Therapeutics, Inc. – Pipeline By Route of Administration, 2012 22
Acorda Therapeutics, Inc. – Pipeline Products By Mechanism of Action, 2012 23
Acorda Therapeutics, Inc. – Recent Pipeline Updates, 2012 24
Acorda Therapeutics, Inc. - Dormant Developmental Projects,2012 25
Acorda Therapeutics, Inc., Subsidiaries 30
Acorda Therapeutics, Inc., Deals Summary 43
Acorda Therapeutics Acquires Aminopyridine and Pre-Clinical Assets From Neurorecovery 44
Acorda Therapeutics Acquires US Rights Of Zanaflex From Elan 46
Acorda Therapeutics Raises $10 Million From Paul Capital 48
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 50
Acorda Therapeutics Enters Into Licensing Agreement With Medtronic For AC105 51
Biogen Idec Enters Into An Agreement With Acorda Therapeutics 53
Acorda Therapeutics Completes Public Offering Of $131 Million 55
Acorda Therapeutics Completes Public Offering Of $67 Million 57
Acorda Therapeutics Completes Public Offering Of $80 Million 59
Acorda Therapeutics Completes Private Placement Of $31.5 Million 61
Acorda Therapeutics Completes IPO Of $36.45 Million 63
Acorda Therapeutics Completes Private Placement Of $11.5 Million 65
Acorda Therapeutics To Acquire Neuronex For Up To $141 Million 66

List of Figures
Acorda Therapeutics, Inc. – Pipeline by Indication, 2012 8
Acorda Therapeutics, Inc. – Pipeline by Stage of Development, 2012 9
Acorda Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012 10
Acorda Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012 20
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/2194014

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Apr 19th 2014
6:30:25 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Acorda Therapeutics, Inc. - Product Pipeline Review - 2012

Web Address

http://www.researchandmarkets.com/reports/2194014

Office Code

OC8DINPOQRUQRS

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EUR 368
Electronic (PDF) - Site License EUR 735
Electronic (PDF) - Enterprisewide EUR 1103

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Apr 19th 2014
6:30:25 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)